A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, Reuters writes ...

In connection with wellness and health improvement efforts, one big change is the area of breast cancer screenings: In 2026, ...

Employers surveyed by the Business Group on Health are bracing for the largest annual increase in healthcare costs in more ...

Tools like Claimable and Fight Health Insurance use AI to guide people through the insurance appeals process and generate ...

Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both of Novo Nordisk's GLP-1 drugs, Ozempic ...

Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.

Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from ...

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...